American Biotech Labs Announces Results of Preliminary Tests for Multiple Avian Bird Flu Strains Using Patented ABL SilverSol Technology(TM)

    Clifton Mining Company Inc. (OTC : CFTN)

    In separate in vitro tests against two strains of the H5N1 avian bird flu
    subtype, both instances of the virus were successfully neutralized by the
    American Biotech Labs' ABL SilverSol Technology products; the most recent
    findings are consistent with prior test using company products against
    the H3N2 and H1N1 flu subtypes.

    SALT LAKE CITY, Oct. 9 /CNW/ - American Biotech Labs (ABL;, creator of a line of powerful products that
utilize patented ABL SilverSol Technology(TM) to combat many of the world's
most harmful pathogens, today announced successful preliminary results on
tests performed using the company's products against three strains of the
avian bird flu virus.
    Preliminary in vitro tests performed by two separate independent
laboratories, using the company's ABL SilverSol Technology(TM) at 10 parts per
million against two strains of the H5-N1 and H3-N2 subtype of the Avian Bird
Flu virus, indicated that the ABL products could neutralize the virus.
    "While we understand that these are preliminary studies, we are extremely
encouraged by the results of this initial testing," said Keith Moeller, a
managing director at American Biotech Labs. "Our intent with these studies is
to test the ability of the product to disarm or kill the Avian flu virus in a
laboratory setting. It is a necessary and valuable next step in our continued
efforts to gain an understanding of what this technology can do."
    The preliminary results of the tests using ABL products against the H5N1
avian bird flu virus are consistent with a variety of previous tests conducted
using company products against the H3N2 and H1N1 flu subtypes. In all cases,
ABL SilverSol Technology(TM) was able to successfully neutralize the virus.
    ABL is engaged in continuing testing and study programs with a variety of
groups and labs in the United States and other nations examining the potential
applications of ABL SilverSol Technology(TM).

    About American Biotech Labs

    American Biotech Labs (ABL;, founded in
1998, utilizes patented processes and technology to create singularly powerful
and effective nano-catalytic silver products. In extensive testing performed
by a variety of respected laboratories and researchers, ABL's nano-catalytic
silver hydrosol has consistently demonstrated the ability to destroy a wide
range of microbes - bacteria, viruses and molds. ABL products can be found at
GNC and other fine health food stores under the Silver Biotics(R) label.
    Clifton Mining Company owns approximately 23% of ABL. Clifton trades on
the U.S. OTC: (CFTN).

    Note: Any statements released by Clifton Mining Company that are forward
looking are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Editors and investors are cautioned
that forward looking statements invoke risk and uncertainties that may affect
the company's business prospects and performance.

For further information:

For further information: Dr. Ken Friedman, President at (303) 642-0659;
Keith Moeller, Vice President at (801) 756-1414 or see our website at

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890